Chemical companies are racing to create new drugs that could be the first to trigger cancer.
“This is a new class of cancer-fighting drugs,” says Robert Lohr, chief executive of Aroma Pharmaceuticals, the company behind aroma and other aroma drugs.
“We don’t know yet if it’s going to have side effects, but we’re working with the FDA to get approval.”
The FDA has not approved a single drug made by Aroma, but the company has received a lot of interest in the subject.
Lohre is looking to the early 1990s, when the company first began using the aroma-derived compound, aranacid, to treat a rare and potentially deadly type of lymphoma in mice.
Aranacids are compounds found in plants that can trigger the cell death of certain types of cells.
Aranacids have been found to cause tumors in a number of different types of human cancers, including leukemia, breast cancer, and prostate cancer.
But their potential use in humans has remained unclear.
Aroma is not alone in its efforts to find a new cancer-preventing agent.
In April, the FDA approved a new drug called CDP-19-6, a chemical compound that has been shown to have anti-cancer properties in animal models.
The drug, which is manufactured by BioTec and is available only in Europe, is a combination of a compound called neomycin and the aran-like compound aranocarban.
Although the FDA has yet to approve a single aroma drug, Lohra says the company plans to get clearance for its next step, a combination drug called nanopurinol.
Nanopurs is a compound that is not derived from aranaclids, but it does contain arananacin, a compound known to cause tumor cell death in animal and human models.
Lothar J. Hofmann, a molecular biologist at the University of Vienna in Austria, says it is possible to create nanopurins that can have similar effects.
Lohr says he hopes to test the drug in humans as early as 2018.
The FDA approved Aroma’s new compound in May, but there is no indication that it will ever be used in humans.
The agency has not yet approved a drug made with aranascarban, a different compound, but Lohrs has expressed interest in creating a drug for aranachromosoma.
While the drug is in the early stages of development, Lothra says Aroma is already working with a biotechnology company to develop the drug and has started working with another company to get the FDA approval.